Haemair was founded in 2005 by engineers with close relatives who had suffered and died of lung disease.
From the outset, the vision was of a device that would directly oxygenate blood to augment residual lung capacity and ultimately provide an alternative to lung transplant.
In over ten years, the company has attracted investment of over £3million from a core group who hope ultimately to gain a return on their investment, but whose primary motivation is to help lung-disease sufferers and their families.
The Company moved to the Swansea University site in 2006 in order to benefit from the world-leading research in blood rheology coming from the collaboration between the Engineering and Medical Schools.
We have succeeded in recruiting a young talented team of scientists and engineers who share our vision.
Our innovative technology recognised by both the Welsh and UK Governments to the extent that we have received R&D grants in excess of £2million.
The improvements incorporated in our innovative design have already attracted the interest of a major multinational medical device company with whom we now have a distribution contract to cover the whole of the European Economic Area and Canada.
We are currently establishing a manufacturing facility designed to meet our needs for 3 to 4 years.